Daraxonrasib Phase 3 Trial Shows Doubled Overall Survival in Metastatic Pancreatic Cancer (worksinprogress.co)

• Daraxonrasib (RMC-6236) is a molecular glue that targets active RAS via Cyclophilin A, forming an inhibitory tri-complex.
• Phase 3 trial results announced April 2026 show daraxonrasib doubled median overall survival in metastatic pancreatic cancer (13.2 vs. 6.6 months).
• Resistance mutations (e.g., Y64D) and KRAS amplification have been identified, underscoring the need for combination strategies.

"Revolution Medicines' daraxonrasib, a molecular glue targeting RAS, doubled median overall survival to 13.2 months versus standard chemotherapy in metastatic pancreatic cancer patients in a Phase 3 trial reported in April 2026. The drug binds Cyclophilin A to form a tri-complex that blocks active RAS, overcoming the protein's previously 'undruggable' status. Resistance mechanisms have been identified, including Y64 mutations and KRAS amplification, prompting calls for combination therapies and streamlined early-phase trials."